4//SEC Filing
DiRocco Derek 4
Accession 0000905148-25-002177
CIK 0001781174other
Filed
Jun 16, 8:00 PM ET
Accepted
Jun 17, 6:04 PM ET
Size
17.6 KB
Accession
0000905148-25-002177
Insider Transaction Report
Form 4
DiRocco Derek
Director
Transactions
- Award
Stock Option (Right to Buy)
2025-06-13+20,275→ 20,275 totalExercise: $1.20Exp: 2035-06-12→ Common Stock (20,275 underlying)
Footnotes (2)
- [F1]The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date.
- [F2]Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund II. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.
Documents
Issuer
Acrivon Therapeutics, Inc.
CIK 0001781174
Entity typeother
Related Parties
1- filerCIK 0001792061
Filing Metadata
- Form type
- 4
- Filed
- Jun 16, 8:00 PM ET
- Accepted
- Jun 17, 6:04 PM ET
- Size
- 17.6 KB